OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Operating Expenses
OSE Immunotherapeutics SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Operating Expenses
-€37.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-22%
|
|
|
Valneva SE
PAR:VLA
|
Operating Expenses
-€220.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Expenses
-€71.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-13%
|
|
|
Inventiva SA
PAR:IVA
|
Operating Expenses
-€102.9m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Operating Expenses
-$125.5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-14%
|
|
|
Abivax SA
PAR:ABVX
|
Operating Expenses
-€233.9m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Operating Expenses?
Operating Expenses
-37.6m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Operating Expenses amounts to -37.6m EUR.
What is OSE Immunotherapeutics SA's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-22%
Over the last year, the Operating Expenses growth was -28%. The average annual Operating Expenses growth rates for OSE Immunotherapeutics SA have been 11% over the past three years , -6% over the past five years , and -22% over the past ten years .
